GSTT1 Gene Test (Glutathione S-Transferase Theta 1)

• Identify whether you have the GSTT1 "present" genotype with functional enzyme activity or the GSTT1 "null" genotype with complete loss of GSTT1 enzyme function.
• Help explain why you may be more sensitive to tobacco smoke, diesel and industrial fumes, solvents, or certain chemicals than peers, or why markers of oxidative stress, lung function, or vascular health drift despite similar lifestyles.
• Inform personalised strategies around exposure reduction, antioxidant and glutathione support, and monitoring frequency, particularly if you lack GSTT1 activity and have higher environmental exposures.
• Provide context for cancer and chronic disease risk in settings with high toxic load, especially when combined with smoking, pollution, or other detox gene variants.
• Clarify your baseline electrophile detoxification capacity alongside lung, liver, kidney, and inflammatory biomarkers, so prevention and longevity plans can focus on changes that move the needle most for your biology.

GSTT1 encodes glutathione S‑transferase Theta 1, a cytosolic phase II detoxification enzyme in the Theta class of the glutathione S‑transferase (GST) superfamily. These enzymes catalyse the conjugation of reduced glutathione (GSH) to a range of electrophilic and hydrophobic compounds, making them more water soluble and easier to excrete.

A common homozygous deletion, known as the GSTT1 null genotype, removes the entire gene and leads to complete absence of GSTT1 protein and activity. Individuals with at least one functional copy (present genotype) produce the enzyme. GSTT1 contributes to detoxification of small electrophiles, including certain epoxides, halogenated compounds, and reactive species generated from 1,3‑butadiene and other combustion products.

GSTT1 sits at a critical junction in detoxification pathways by catalysing glutathione conjugation of specific low molecular weight electrophiles. For example, it helps neutralise diepoxide metabolites of 1,3‑butadiene, a potent carcinogen found in cigarette smoke and industrial emissions, by forming glutathione conjugates that can be cleared via the mercapturic acid pathway.

Alongside this, GSTT1 also contributes to detoxification of reactive oxygen species derived products and some environmental and occupational chemicals. When GSTT1 is absent, these electrophiles rely more heavily on other GSTs and antioxidant systems for detoxification, which can alter the pattern of DNA, protein, and lipid damage under high exposure or oxidative stress.

GSTT1 contributes to three interconnected systems: detoxification of environmental and occupational toxins, protection of lung and vascular tissues, and long‑term cancer and cardiometabolic risk. In the lung, GSTT1 helps clear reactive epoxides and aldehydes from tobacco smoke and polluted air, which can otherwise damage airway cells and contribute to chronic obstructive pulmonary disease and lung cancer risk in the context of heavy exposure.

In blood vessels and organs such as kidney and liver, GSTT1-dependent conjugation helps limit accumulation of reactive intermediates that drive oxidative stress, inflammation, and structural damage. The GSTT1 null genotype has been associated in some studies with altered risk of type 2 diabetes, changes in lipid patterns, and differences in cardiovascular, cancer, or inflammatory disease susceptibility, particularly when combined with smoking or high toxic load. The effect size is modest and highly context dependent.

It is easy to assume that GSTT1 testing and liver function or general "detox" blood panels tell you the same story, but they answer different questions. GSTT1 genotyping asks whether you have the genetic capacity to produce this specific Theta class glutathione S‑transferase or whether the enzyme is completely absent. This result does not change over time.

Liver enzymes, kidney markers, oxidative stress markers, and inflammation show how your organs and antioxidant systems are coping right now with your current exposures, lifestyle, and health status. They may remain normal in GSTT1 null individuals if exposures are low and other detox systems compensate, and they can be abnormal in GSTT1 present individuals if toxic load or other stresses are high. Combining genotype and phenotype provides a more complete picture of risk and resilience.

The influence of GSTT1 present or null genotypes is shaped much more by environment, co‑existing pathways, and lifestyle than by the gene alone, which means you have meaningful room to change the trajectory. Several modifiable factors can either buffer genetic effects or amplify them.

• Smoking and air pollution: Tobacco smoke and polluted air contain many GSTT1 substrates, including 1,3‑butadiene-derived epoxides. In GSTT1 null individuals, these exposures can cause more oxidative stress and damage, making smoking cessation and pollution reduction especially important.
• Occupational exposures: Work with combustion products, rubber, petrochemicals, or certain solvents increases electrophile burden. Protective equipment, ventilation, and role design become more critical when GSTT1 activity is absent.
• Diet quality and antioxidant intake: Diets rich in fruits, vegetables, and other sources of antioxidants and phytochemicals support glutathione status and Nrf2-mediated upregulation of other detox systems, which can help compensate for GSTT1 loss. Poor diet quality amplifies oxidative stress, particularly in null genotypes.
• Overall glutathione status: Adequate protein, sulphur amino acids, and micronutrients that support glutathione synthesis help maintain detoxification capacity across all GST classes. Low glutathione reserve makes the absence of GSTT1 more impactful.
• Co-existing detox and antioxidant genes: Polymorphisms in GSTM1, GSTP1, EPHX1, and other detox or antioxidant enzymes can compound or buffer GSTT1 effects. Considering GSTT1 as part of a wider detox profile is more informative than viewing it in isolation.
• Systemic inflammation and metabolic health: Chronic inflammation, obesity, insulin resistance, and poor sleep increase oxidative stress and reactive species production, which can stress detox systems more heavily, especially when GSTT1 activity is missing.

Yes, and this is very common. Many people with the GSTT1 null genotype do not experience any clear, direct symptoms attributable to this gene and may only discover their status through DNA testing.

Health issues linked to GSTT1 variation, such as increased susceptibility to certain toxins or modest shifts in disease risk, typically emerge over years and only in combination with specific exposures and other risk factors. Symptoms like fatigue, headaches, or "chemical sensitivity" are non‑specific and can reflect many influences beyond GSTT1 status.

GSTT1 genotypes mainly differ in whether the gene is present or completely deleted, which determines whether any GSTT1 protein is produced. Understanding your pattern can help tailor exposure reduction and organ monitoring rather than treating detoxification capacity as fixed and opaque.

• GSTT1 present (insertion genotype): At least one copy of the GSTT1 gene is present, so functional enzyme can be produced. Detoxification of GSTT1 substrates is available, although actual activity still depends on glutathione status, Nrf2 signalling, and overall exposures.
• GSTT1 null (homozygous deletion): Both copies of the GSTT1 gene are deleted, and no GSTT1 enzyme is produced. Detoxification of GSTT1-specific substrates depends entirely on other GSTs and antioxidant pathways. This genotype has been linked to altered sensitivity to tobacco smoke and environmental toxins and modest changes in risk for some cancers and cardiometabolic conditions in certain populations.
• Combined GSTT1 and other GST genotypes: The overall detox profile emerges from the combination of GSTT1 with GSTM1, GSTP1, and other GST family members. For example, dual null GSTM1/GSTT1 genotypes may have a larger impact on susceptibility to specific toxins than either alone.

For DNA-based GSTT1 testing, preparation is simple because your genotype does not change with recent diet, exposures, or medications. The key step is choosing a panel that places GSTT1 alongside other detox genes, blood markers, and lifestyle factors so the results translate into practical steps.

Standalone GSTT1 genotyping using blood or saliva does not require fasting. If GSTT1 is bundled with liver enzymes, oxidative stress markers, lung function, or cardiometabolic panels, your clinician or testing instructions may suggest avoiding heavy exercise, alcohol, or unusual exposures just before testing to capture a clean baseline.

A GSTT1 test is most valuable when the result will influence how you approach exposures, antioxidant support, and long‑term monitoring, rather than as a curiosity in isolation. It becomes particularly informative when interpreted alongside lifestyle, environment, and organ-level biomarkers.

• Current or past smoking, or high pollution exposure: If you smoke, have smoked, or live or work in polluted or high‑traffic environments, GSTT1 genotyping can help clarify susceptibility and underscore the importance of exposure reduction and lung monitoring.
• Occupational toxin exposure: In roles involving combustion products, solvents, or specific industrial chemicals, GSTT1 status can support discussions about protective measures, health surveillance, and potential role modifications.
• Family or personal history of toxin-related disease: In families with clustering of certain cancers, cardiovascular disease, or kidney issues in the context of high exposure, GSTT1 testing adds context for individual risk and prevention strategies.
• Building a detoxification and longevity roadmap: Within a comprehensive DNA and blood testing approach, GSTT1 provides a durable anchor for environmental and lifestyle decisions that support healthy ageing.